Kura Oncology
KURA
10.40
-0.27
-2.55%
Kura Oncology
US · KURA
#3283 by market cap
Listed 2015
10.40
-0.27
-2.55%
Live - 5344 symbols - heartbeat 516s ago
· 2026-10-08 09:59
Pre-market
10.48
-1.78%
After-hours
10.67
0.00%
- Market cap
- 925.01M
- P/E (TTM)i
- -3.09
- P/Bi
- 19.11
- EPSi
- -3.18
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on KURA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- Total institutional ownership rose 0.1 percentage points.
Institutional ownership
- Held by institutions
- 99.52% +0.13pp
- Institutions
- 271
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund53.11%
Hedge Fund35.53%
Public Company4.89%
VC/PE Fund4.10%
Individual/Insider1.59%
Private Company1.24%
Government Pension Fund0.40%
Insurance Company0.18%
Top holders as of 2026-06-30
BlackRock
11.81% · 10.51M sh
Montanova Capital, LLC
9.64% · 8.58M sh
BVF Partners L.P.
9.49% · 8.45M sh
State Street Global Advisors
5.99% · 5.33M sh
Vanguard Capital Management, LLC
5.11% · 4.55M sh
Armistice Capital LLC
4.13% · 3.68M sh
AQR Capital Management
3.46% · 3.08M sh
Geode Capital Management, LLC
2.51% · 2.23M sh
Alethea Capital Management, LLC
2.44% · 2.17M sh
Prosight Management, LP
2.27% · 2.02M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Troy Wilson | Chairperson & CEO | 1.16% |
| Kathleen Ford | Chief Operating Officer | 0.10% |
| Teresa Bair | Chief Legal Officer | 0.08% |
| Thomas Doyle | Senior VP of Finance & Accounting | 0.08% |
| Francis Burrows | Senior Vice President of Translational Research | 0.05% |
| Mollie Leoni | Executive Vice President of Clinical Development | 0.05% |
| Faheem Hasnain | Lead Independent Director | 0.03% |
| Brian Powl | Chief Commercial Officer | 0.02% |
| Thomas Malley | Independent Director | 0.01% |
| Stephen Dale | Chief Medical Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-28 | Kathleen Ford | Chief Operating Officer | Automatic Disposition | -3,668 | $10.75 |
| 2026-09-28 | Brian Powl | Chief Commercial Officer | Automatic Disposition | -23,430 | $10.56–10.75 |
| 2026-09-28 | Brian Powl | Chief Commercial Officer | Intent to Sell (Form 144) | -15,430 | $10.61 |
| 2026-09-28 | Mollie Leoni | Executive Vice President of Clinical Development | Automatic Disposition | -28,802 | $10.75 |
| 2026-09-27 | Teresa Bair | Chief Legal Officer | Open Market Disposition | -8,442 | $10.50 |
| 2026-09-27 | Kathleen Ford | Chief Operating Officer | Open Market Disposition | -6,906 | $10.50 |
| 2026-09-27 | Brian Powl | Chief Commercial Officer | Open Market Disposition | -9,020 | $10.50 |
| 2026-09-27 | Mollie Leoni | Executive Vice President of Clinical Development | Open Market Disposition | -12,448 | $10.50 |
| 2026-09-27 | Thomas Doyle | Senior VP of Finance & Accounting | Open Market Disposition | -4,607 | $10.50 |
| 2026-09-23 | Francis Burrows | Senior Vice President of Translational Research | Derivative Exercise and Sale | -20,726 | $6.15–10.83 |
| 2026-09-23 | Francis Burrows | Senior Vice President of Translational Research | Derivative Exercise and Retained | +9,274 | $6.15 |
| 2026-09-07 | Jennifer Fulk | Chief Financial Officer | Other Derivative Acquisition | +450,000 | $12.52 |
| 2026-08-23 | Troy Wilson | Chairperson & CEO | Open Market Acquisition | +100,000 | $12.39 |
| 2026-08-20 | Brian Powl | Chief Commercial Officer | Open Market Disposition | -4,345 | $11.89 |
| 2026-08-18 | Teresa Bair | Chief Legal Officer | Automatic Disposition | -31,487 | $12.63 |
| 2026-08-16 | Troy Wilson | Chairperson & CEO | Open Market Acquisition | +100,000 | $11.12 |
| 2026-06-17 | Mollie Leoni | Executive Vice President of Clinical Development | Automatic Disposition | -84,929 | $9.82 |
| 2026-06-03 | Diane Parks | Independent Director | Other Derivative Acquisition | +35,000 | $8.77 |
| 2026-06-03 | Thomas Malley | Independent Director | Other Derivative Acquisition | +35,000 | $8.77 |
| 2026-06-03 | Mary Szela | Independent Director | Other Derivative Acquisition | +35,000 | $8.77 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:59:52 · For reference only, not investment advice and not tailored to your situation.